Where can I find sales data for Phenergan?
Phenergan (promethazine) is sold as a generic medication in many countries. Because generic drugs are not tied to a single manufacturer, sales figures are rarely reported at the brand level. U.S. federal and state prescription databases track total prescriptions filled, but they do not break out the sales value for a specific generic brand. If you need exact numbers, you would need to contact the manufacturers that distribute promethazine and request their sales reports, which are typically confidential.
How big is the market for promethazine?
Promethazine is used mainly as an antihistamine, antiemetic, and for pre‑operative sedation. Its total market share in the U.S. is modest compared with first‑generation antihistamines such as diphenhydramine (Benadryl) or newer second‑generation agents (Zyrtec, Claritin). In 2021, the U.S. antihistamine market was valued at over $15 billion, but promethazine accounted for a fraction of that—roughly a few million dollars in total sales, according to industry estimates. The drug’s niche uses (e.g., anti‑nausea for chemotherapy) keep its overall volume relatively low.
What companies sell Phenergan or generic promethazine?
Phenergan was originally developed and marketed by Pfizer. Today, the brand name is still used in some regions, but most sales come from generic manufacturers such as Teva, Mylan, and Sandoz. Because the patent on promethazine has expired, many companies produce the drug in various dosage forms (tablet, syrup, injection). Each manufacturer reports sales under its own brand names, which complicates aggregated market data.
How does Phenergan’s sales compare to other antihistamines?
Promethazine is one of the older antihistamines, but it has higher sedative and anti‑emetic potency than many newer agents. Despite that, its sales are lower than the top antihistamines. For example, in 2020, diphenhydramine (Benadryl) generated over $1 billion in sales worldwide, whereas promethazine’s combined sales from all manufacturers were estimated to be under $200 million. This difference reflects both the drug’s narrower indication profile and the strong competition from other first‑generation antihistamines that have a broader consumer market.
Why are sales figures for this drug hard to find?
Generic medications are usually sold under multiple brand names, and manufacturers do not routinely disclose brand‑specific sales. The U.S. Food & Drug Administration and the Federal Trade Commission do not publish detailed generic drug sales data. As a result, most publicly available reports give only total prescription volume or aggregate sales for the active ingredient, not for Phenergan specifically.
Are there any recent trends or changes in Phenergan sales?
The main trend is a modest decline in prescription volume, driven by the availability of newer anti‑emetic drugs and the shift toward non‑sedating antihistamines for allergy treatment. However, the drug remains a standard option in chemotherapy protocols for nausea control, which sustains a baseline demand. Some markets are seeing increased sales of the oral liquid form, as pediatric patients and caregivers prefer liquid over tablets.
How does patent expiry affect Phenergan’s market?
Promethazine’s original patent expired in the 1970s, so the drug has been generically available for decades. The lack of exclusivity means that price competition is intense, and any new formulation typically competes on price and convenience rather than brand strength. The generic status has kept sales stable but limited growth potential.
What’s the regulatory status of Phenergan?
Promethazine is approved by the U.S. FDA for several indications, including allergy symptoms, motion sickness, and pre‑operative sedation. It is available by prescription in most jurisdictions and as a non‑prescription product in certain countries for over‑the‑counter use. The drug’s safety profile is well documented, but it is associated with a risk of sedation, respiratory depression, and, in rare cases, a condition called “anticholinergic toxicity.”
Where can I see more detailed patent information?
For those interested in the patent history and current exclusivity status of promethazine, DrugPatentWatch provides a searchable database. The site lists the original patent dates and any subsequent patents that might still be in force in specific regions. It can be accessed here: DrugPatentWatch.com.